Muller & Phipps (India) Ltd
Incorporated in 1917, Muller & Phipps (India) is engaged in marketing of over the counter medical preparation and home care products.
- Market Cap ₹ 35.6 Cr.
- Current Price ₹ 570
- High / Low ₹ 726 / 173
- Stock P/E
- Book Value ₹ -23.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.05% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4.26 | 3.67 | 4.50 | 3.47 | 3.40 | 3.13 | 3.74 | 3.61 | 3.97 | 3.67 | 3.91 | 4.14 | 4.25 | |
4.89 | 3.75 | 4.88 | 3.60 | 3.40 | 3.10 | 3.37 | 3.51 | 3.72 | 3.50 | 3.87 | 4.18 | 4.94 | |
Operating Profit | -0.63 | -0.08 | -0.38 | -0.13 | 0.00 | 0.03 | 0.37 | 0.10 | 0.25 | 0.17 | 0.04 | -0.04 | -0.69 |
OPM % | -14.79% | -2.18% | -8.44% | -3.75% | 0.00% | 0.96% | 9.89% | 2.77% | 6.30% | 4.63% | 1.02% | -0.97% | -16.24% |
0.13 | 0.18 | 1.14 | 0.38 | 0.30 | 0.19 | 0.09 | 0.40 | 1.61 | 0.38 | 0.26 | 0.83 | 0.82 | |
Interest | 0.54 | 0.31 | 0.31 | 0.31 | 0.24 | 0.24 | 0.21 | 0.14 | 0.12 | 0.10 | 0.08 | 0.06 | 0.05 |
Depreciation | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Profit before tax | -1.07 | -0.24 | 0.44 | -0.07 | 0.05 | -0.03 | 0.24 | 0.35 | 1.73 | 0.44 | 0.21 | 0.72 | 0.08 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 20.00% | 0.00% | 20.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
-1.08 | -0.23 | 0.44 | -0.07 | 0.04 | -0.03 | 0.19 | 0.35 | 1.73 | 0.43 | 0.21 | 0.73 | 0.08 | |
EPS in Rs | -17.28 | -3.68 | 7.04 | -1.12 | 0.64 | -0.48 | 3.04 | 5.60 | 27.68 | 6.88 | 3.36 | 11.68 | 1.28 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | 2% |
3 Years: | 1% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 12% |
3 Years: | -5% |
TTM: | -154% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 91% |
3 Years: | 55% |
1 Year: | 166% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
Reserves | -5.72 | -5.96 | -5.52 | -5.59 | -5.52 | -5.55 | -5.35 | -4.98 | -3.29 | -2.86 | -2.65 | -1.92 | -2.12 |
1.73 | 1.87 | 1.86 | 1.85 | 1.85 | 1.85 | 2.00 | 1.86 | 1.59 | 1.31 | 1.04 | 0.77 | 0.73 | |
7.93 | 7.87 | 7.70 | 7.60 | 7.63 | 7.54 | 7.53 | 7.37 | 5.74 | 5.76 | 5.95 | 5.78 | 6.21 | |
Total Liabilities | 4.57 | 4.41 | 4.67 | 4.49 | 4.59 | 4.47 | 4.81 | 4.88 | 4.67 | 4.84 | 4.97 | 5.26 | 5.45 |
0.12 | 0.09 | 0.08 | 0.07 | 0.04 | 0.05 | 0.04 | 0.07 | 0.07 | 0.06 | 0.05 | 0.06 | 0.06 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
4.45 | 4.32 | 4.59 | 4.42 | 4.55 | 4.42 | 4.77 | 4.81 | 4.60 | 4.78 | 4.92 | 5.20 | 5.39 | |
Total Assets | 4.57 | 4.41 | 4.67 | 4.49 | 4.59 | 4.47 | 4.81 | 4.88 | 4.67 | 4.84 | 4.97 | 5.26 | 5.45 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.32 | -0.07 | 0.53 | 0.03 | 0.07 | 0.16 | -0.01 | 0.15 | 2.16 | 0.11 | 0.21 | 0.72 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.02 | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | -0.02 | |
-0.32 | 0.09 | -0.50 | -0.04 | -0.03 | -0.07 | 0.10 | -0.26 | -1.76 | -0.38 | -0.34 | -0.32 | |
Net Cash Flow | 0.00 | 0.02 | 0.03 | -0.01 | 0.04 | 0.07 | 0.09 | -0.14 | 0.39 | -0.27 | -0.13 | 0.39 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 33.42 | 31.83 | 51.10 | 50.49 | 59.04 | 40.81 | 40.01 | 30.33 | 45.05 | 71.61 | 88.68 | 73.18 |
Inventory Days | 13.04 | 4.03 | 3.13 | 2.04 | 8.44 | 13.42 | 16.17 | 34.30 | 26.55 | 45.03 | 36.08 | 32.09 |
Days Payable | 498.62 | 580.77 | 466.82 | 530.17 | 535.90 | 652.17 | 552.12 | 580.57 | 455.70 | 504.84 | 481.72 | 429.18 |
Cash Conversion Cycle | -452.16 | -544.91 | -412.59 | -477.64 | -468.41 | -597.94 | -495.94 | -515.94 | -384.10 | -388.20 | -356.96 | -323.91 |
Working Capital Days | -357.29 | -437.60 | -313.09 | -429.16 | -425.12 | -478.12 | -391.35 | -387.24 | -186.64 | -173.05 | -152.16 | -140.18 |
ROCE % |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Nov
-
Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
13 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
13 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Intimation for Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024
5 Nov - Notice of Board Meeting on November 13, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1]
a) Cavisan - Medicated Dental Cream[2]
b) Cavifast - Medicated Dental Cream[3]
c) Cavisan - Gum Astringent[4]
d) Nixoderm[5]